Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Department of Pediatric Oncology, Johns Hopkins Hospital, Baltimore, Maryland.
Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Transplant Cell Ther. 2022 Jan;28(1):31.e1-31.e9. doi: 10.1016/j.jtct.2021.10.011. Epub 2021 Oct 20.
Hematopoietic stem cell transplantation (HSCT) may be used to consolidate chimeric antigen receptor (CAR) T cell therapy-induced remissions for patients with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL), but little is known about the factors impacting overall survival (OS) and event-free survival (EFS) for post-CAR hematopoietic stem cell transplantation (HSCT). The present study's primary objective was to identify factors associated with OS and EFS for consolidative HSCT following CAR-induced complete remission (CR) in transplantation-naïve patients. Secondary objectives included evaluation of OS/EFS, relapse-free survival and cumulative incidence of relapse for all patients who proceeded to HSCT, stratified by first and second HSCT, as well as the tolerability of HSCT following CAR-induced remission. This was a retrospective review of children and young adults enrolled on 1 of 3 CAR T cell trials at the National Cancer Institute targeting CD19, CD22, and CD19/22 (ClinicalTrials.gov identifiers NCT01593696, NCT02315612, and NCT03448393) who proceeded directly to HSCT following CAR T cell therapy. Between July 2012 and February 2021, 46 children and young adults with pre-B ALL went directly to HSCT following CAR therapy. Of these patients, 34 (74%) proceeded to a first HSCT, with a median follow-up of 50.8 months. Transplantation-naïve patients were heavily pretreated prior to CAR T cell therapy (median, 3.5 lines of therapy; range, 1 to 12) with significant prior immunotherapy exposure (blinatumomab, inotuzumab, and/or CAR T cell therapy in patients receiving CD22 or CD19/22 constructs (88%; 15 of /17)). Twelve patients (35%) had primary refractory disease, and the median time from CAR T cell infusion to HSCT Day 0 was 54.5 days (range, 42 to 127 days). The median OS following first HSCT was 72.2 months (95% confidence interval [CI], 16.9 months to not estimable [NE]), with a median EFS of 36.9 months (95% CI, 5.2 months to NE). At 12 and 24 months, the OS was 76.0% (95% CI, 57.6% to 87.2%) and 60.7% (95% CI, 40.8% to 75.8%), respectively, and EFS was 64.6% (95% CI, 46.1% to 78.1%) and 50.9% (95% CI, 32.6% to 66.6%), respectively. The individual factors associated with both decreased OS and EFS in univariate analyses for post-CAR consolidative HSCT in transplantation-naïve patients included ≥5 prior lines of therapy (not reached [NR] versus 12.4 months, P = .014; NR versus 4.8 months, P = .063), prior blinatumomab therapy (NR versus 16.9 months, P = .0038; NR versus 4.4 months, P = .0025), prior inotuzumab therapy (NR versus 11.5 months, P = .044; 36.9 months versus 2.7 months, P = .0054) and ≥5% blasts (M2/M3 marrow) pre-CAR T cell therapy (NR versus 17 months, P = .019; NR versus 12.2 months, P = .035). Primary refractory disease was associated with improved OS/EFS post-HSCT (NR versus 21.9 months, P = .075; NR versus 12.2 months, P = .024). Extensive prior therapy, particularly immunotherapy, and high disease burden each individually adversely impacted OS/EFS following post-CAR T cell consolidative HSCT in transplantation-naïve patients, owing primarily to relapse. Despite this, HSCT remains an important treatment modality in long-term cure. Earlier implementation of HSCT before multiply relapsed disease and incorporation of post-HSCT risk mitigation strategies in patients identified to be at high-risk of post-HSCT relapse may improve outcomes.
造血干细胞移植(HSCT)可用于巩固嵌合抗原受体(CAR)T 细胞治疗诱导的缓解,以治疗复发/难治性 B 细胞急性淋巴细胞白血病(B-ALL)患者,但对于 CAR 后 HSCT 后总生存(OS)和无事件生存(EFS)的影响因素知之甚少。本研究的主要目的是确定 CAR 诱导完全缓解(CR)后巩固性 HSCT 与 OS 和 EFS 相关的因素,纳入对象为移植初治患者。次要目标包括评估所有接受 HSCT 的患者的 OS/EFS、无复发生存率和累积复发率,根据首次和第二次 HSCT 进行分层,并评估 CAR 缓解后 HSCT 的耐受性。这是对美国国立癌症研究所针对 CD19、CD22 和 CD19/22 的 3 项 CAR T 细胞试验中 1 项的儿童和年轻成人患者的回顾性分析(ClinicalTrials.gov 标识符:NCT01593696、NCT02315612 和 NCT03448393),这些患者在 CAR T 细胞治疗后直接进行 HSCT。2012 年 7 月至 2021 年 2 月,46 例前 B 细胞 ALL 患儿在 CAR 治疗后直接进行 HSCT。其中 34 例(74%)进行了首次 HSCT,中位随访时间为 50.8 个月。CAR T 细胞治疗前,移植初治患者接受了大量预处理(中位数,3.5 线治疗;范围,1 至 12),且先前有大量免疫治疗暴露史(blinatumomab、inotuzumab 和/或接受 CD22 或 CD19/22 构建体的 CAR T 细胞治疗的患者(88%;17 例中的 15 例))。12 例(35%)患者为原发性难治性疾病,CAR T 细胞输注至 HSCT 日 0 的中位时间为 54.5 天(范围,42 至 127 天)。首次 HSCT 后的中位 OS 为 72.2 个月(95%CI,16.9 个月至无法估计[NE]),中位 EFS 为 36.9 个月(95%CI,5.2 个月至 NE)。12 个月和 24 个月时,OS 分别为 76.0%(95%CI,57.6%至 87.2%)和 60.7%(95%CI,40.8%至 75.8%),EFS 分别为 64.6%(95%CI,46.1%至 78.1%)和 50.9%(95%CI,32.6%至 66.6%)。在移植初治患者的 CAR 后巩固性 HSCT 中,与 OS 和 EFS 降低相关的单因素分析中,与 OS 和 EFS 降低相关的个体因素包括:≥5 线既往治疗(NR 与 12.4 个月,P=.014;NR 与 4.8 个月,P=.063)、既往blinatumomab 治疗(NR 与 16.9 个月,P=.0038;NR 与 4.4 个月,P=.0025)、既往 inotuzumab 治疗(NR 与 11.5 个月,P=.044;NR 与 2.7 个月,P=.0054)和 CAR T 细胞治疗前≥5%的骨髓原始细胞(M2/M3)(NR 与 17 个月,P=.019;NR 与 12.2 个月,P=.035)。原发性难治性疾病与 HSCT 后 OS/EFS 改善相关(NR 与 21.9 个月,P=.075;NR 与 12.2 个月,P=.024)。先前广泛的治疗,特别是免疫治疗,以及高疾病负担,各自单独对移植初治患者 CAR 后巩固性 HSCT 的 OS/EFS 产生不利影响,主要是由于复发。尽管如此,HSCT 仍然是长期治愈的重要治疗方式。在多发性复发疾病之前更早地实施 HSCT,并在识别为 HSCT 后复发高风险的患者中纳入 HSCT 后风险缓解策略,可能会改善预后。